

***Mycobacterium Tuberculosis* Strain Lineage in Mixed Tribal Population Across India and Andaman Nicobar Island**

Azger Dusthacker V. N. (✉ azger@nirt.res.in)

National Institute of Research in Tuberculosis <https://orcid.org/0000-0002-3616-3675>

Azger Dusthacker V. N.

National Institute for Research in Tuberculosis

Ashok Kumar

National Institute for Research in Tuberculosis

Kannappan Kannappan Sucharitha

New College

S. Shivakumar

National Institute for Research in Tuberculosis

S Raghavi

National Institute for Research in Tuberculosis

S Azhagendran

National Institute for Research in Tuberculosis

S Vetrivel

ICMR-National Institute of Research in Tribal Health

Vikas Gangadhar Rao

ICMR-National Institute of Research in Tribal Health

Rajiv Yadav

ICMR-National Institute of Research in Tribal Health

Vijayachari Paluru

ICMR: Indian Council of Medical Research

Anil Jacob Purthy

Pondicherry University

Tahziba Hussain

Regional Medical Center

Vivek Kashyap

Rajendra Institute of Medical Sciences

K. Rekha Devi

ICMR: Indian Council of Medical Research

Anil Kumar Indira Krishnan

SRM-RI: SRM Research Institute Kattankulathur

Praveen Anand

ICMR: Indian Council of Medical Research

Pradeep Das

Rajendra Memorial Research Institute of Medical Sciences

Avi Kumar Bansal

National Institute of Epidemiology

Madhuchhanda Das

Division of Epidemiology and Communicable diseases

Harpreet Kaur

ICMR: Indian Council of Medical Research

D. Raghunath

ICMR: Indian Council of Medical Research

Rajesh Mondal

ICMR: Indian Council of Medical Research

Beena E Thomas

ICMR: Indian Council of Medical Research

Research Article

Keywords: Clusters, Lineage, Prevalence, M. tuberculosis, Spoligotyping, Tribe

Posted Date: August 4th, 2021

DOI: <https://doi.org/10.21203/rs.3.rs-665868/v1>

License:   This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Abstract

In India, the tribal population constitutes almost 8.6% of the nation's total population. This study attempts to provide information pertaining to the TB strain diversity, its public health implications, and distribution among the tribal population in 10 Indian states and Andaman & Nicobar (A&N) Island. Clinical isolates were received from 66 villages (10 states and island). A total of 78 *M. tuberculosis* clinical isolates were received from 10 different states and A&N Island. Among these, 16 different strains were observed. The major *M. tuberculosis* strains spoligotype belong to the Beijing, CAS1_DELHI, and EAI5 family followed by EAI1_SOM, EAI6_BGD1, LAM3, LAM6, LAM9, T1, T2, U strains. Drug-susceptibility testing (DST) results showed almost 15.4% of clinical isolates found to be resistant to isoniazid (INH) or rifampicin (RMP) + INH. Predominant multidrug-resistant tuberculosis (MDR-TB) isolates seem to be Beijing strain. Beijing, CAS1_DELHI, EAI3_IND, and EAI5 were the principal strains infecting mixed tribal populations across India. Despite the small sample size, this study has demonstrated higher diversity among the TB strains with significant MDR-TB findings. Prevalence of Beijing MDR-TB strains in Central, Southern, Eastern India and A&N Island indicates the transmission of the TB strains.

Introduction

Indian tribal population is one of the highly neglected groups of people due to geographical and cultural barriers in terms of health and associated public health services (Govt of India 2020-21). Tuberculosis (TB) claims about 2 million lives annually and it is the leading cause of mortality worldwide due to a single bacterial agent. The situation is particularly alarming in several developing countries including India, as India accounts for over 30% of the global burden of TB. Besides, the emergence and spread of drug-resistant strains and the synergistic association of these diseases with AIDS are posing major challenges for TB control. Due to the aforesaid reason, the World Health Organization (WHO) has announced tuberculosis as a Global emergency (WHO 2020). Preliminary data indicate the prevalence of TB among the tribal population is 703 per 100,000 populations but there is an urgent need to assess the incidence and strain diversity of *Mycobacterium tuberculosis* (Thomas et al. 2015). According to Rao et al. (2019), more than 70% of the tribal population resides in the central Indian states of the country. Madhya Pradesh in central India accounts for about 21.1% of the tribal population with 46 ethnic groups. To comprehend the transmission dynamics of *M. tuberculosis* strains and their distribution, molecular typing plays a significant role to scrutinize outbreaks in health care settings at a specific region/area (Ameke et al. 2021). Based on the WHO guidelines, TB resistance to at least two drugs (Isoniazid and Rifampicin) was characterized as multidrug-resistant tuberculosis (MDR-TB). MDR-TB epidemics were chiefly focused on transmission than drug resistance acquisition during treatment (Kendall 2015 and Sharma 2017). Spoligotyping, Restriction fragment length polymorphism (IS6110-RFLP) typing/ and Mycobacterial interspersed repetitive unit variable number tandem repeat (MIRU-VNTR) typing are the most used tools for epidemiological strain typing or molecular evolutionary studies of *M. tuberculosis* (Devi et al. 2021). Characterizing *M. tuberculosis* isolates by using Spoligotyping, is a PCR-based reverse hybridization blotting technique established by polymorphism (Gupta et al. 2014; Varma-Basil et al. 2017;

Rahul 2019 and Desikan 2012). Overall genomic differentiation in *M. tuberculosis* is designated by articulating via spoligotyping patterns which eventually depicts the diversity (Said et al. 2009). Our research intended to identify the types of *M. tuberculosis* strains prevalent across several parts of India, A&N Island tribal groups which seem to report different strains and the associated clusters across India. It is the foremost intervention upon mixed tribal populations across India, A&N Island although with limited sample size. Several communal elements such as deprived medical support, pitiable socio-economic, and other medical risk aspects play a significant role featuring the mitigation of TB incidence (Togun et al. 2020). Additionally, the deterioration of the TB situation is mainly due to the progress of drug resistance in *M. tuberculosis* isolates. Our study aimed to estimate the prevalence of *M. tuberculosis* lineages among mixed tribal groups in tribal areas of Central, Southern, Eastern India, and A&N Island.

Materials And Methods

Sampling Sites

In order to study the prevalence of pulmonary tuberculosis among tribal populations in India from April 2015 to March 2020. The large-scale national level tribal tuberculosis prevalence survey of India was carried, evolving different phase studies aged ≥ 15 years in tribal villages. Based on the population proportional to the estimated size (PPES) method, equal weightage was given to the entire country; apparently, the country was divided into 6 zones, each with two or more states. These states comprising East, West, North, South, Central, and North East of almost 88 villages totally selected from 17 states of India. Our research report involves Phase I trial, which covers 66 villages from 10 states and A&N island viz., Madhya Pradesh, Chhattisgarh, Jharkhand, Maharashtra, Odisha, Manipur, Tripura, Rajasthan, Telangana, and Nagaland. 78 clinical isolates were narrowed down from 10 states and A&N Island for further analysis.

Culture identification

The cultures received from the laboratories were sub-cultured on Lowenstein Jensen Media (LJ) and were identified using the MPT64 antigen detection test, growth on P-nitrobenzoic acid (PNB), and Ziehl-Neelsen staining to confirm *Mycobacterium* (<http://www.nirt.res.in/pdf/bact/SOP.pdf>).

Drug Resistance associated mutation

Those cultures identified as *M. tuberculosis*, further subjected to genotypic identification by Genotype MTBDR plus 96 kits to determine the susceptibility for RMP (*rpoB*) & INH (*katG* and *inhA*) by LPA assay (WHO 2007). When the cultures are found to be non-tuberculous mycobacteria (NTM), species identification was performed by a conventional method. Species growth identification done by checking for the growth in the presence of P-nitrobenzoic acid (PNB) by PNB inhibition test and 68°C catalase test were performed as well (Agarwal et al. 2014).

Spoligotyping

Spoligotyping was performed as described by Kamerbeek et al. (1997). DRa and DRb primers were used for amplifying the direct repeat (DR) region in the genome of the *M. tuberculosis* complex. *M. tuberculosis* H37Rv strain and *M. bovis* BCG P3 chromosomal DNA were used as positive controls. The molecular biology grade water served as the negative control. The commercial membrane pre-coated with spacer-oligos, which represents the spacer region of known sequences, was used for hybridizing the amplified product. The membrane was incubated with streptavidin-peroxidase and ECL to visualize the presence/absence of spacer on X-ray film as black squares. The phylogenetic tree was the software used for spoligotyping through the neighbor-joining method with Jaccard's distance. Statistical analyses were performed to find the association between the different states and lineages.

Results

M. tuberculosis clinical isolates distribution

A total of 78 *M. tuberculosis* clinical isolates of several tribal populations among 11 places were studied, samples obtained so far from Phase I study. Madhya Pradesh, Chhattisgarh, Jharkhand, A&N Island, Manipur, Nagaland, Tripura, Rajasthan, Telangana, Andhra Pradesh, and Odisha were the sampling sites. Out of 11 sampling sites, 30 *M. tuberculosis* cultures were from Madhya Pradesh and Chhattisgarh. Whereas 9 *M. tuberculosis* cultures were from A&N island (Harminder bay at Hut bay), comprises 3 Beijing strains and the respective tribal group was Nicobarese. The remaining 10 Beijing strains were reported in Madhya Pradesh, Jharkhand, Manipur, Nagaland, and Tripura respectively (**Figure. 1a**). The respective tribal population in Madhya Pradesh were Bheel, Kol, Baiga, Kokru, Korku, Gond, Bhil, Bhilala, Bhoomiya, Barela, Rathore, Barelapa, Rathiya, Shariya, and Bhiala. Similarly, the remaining predominant Chattisgarh site comprises the following tribes namely; Bhaina, Bheni, Gond, Binjwal, Charwaha, Cherwa, Chirwa, Khairwar, Sawara, Nagesiya, and Urao (**Figure. 1b**).

Lineage Dissemination

According to the lineage dissemination of the classification, the strain types were categorized into lineages 1 to 7 (L1 to L7). Based on this system of heterogeneous grouping, the distribution of strains belonging to lineages 1 to 4 were seen prevalent in Madhya Pradesh with more of L1 (n = 10), while L3 (n = 7) ranked next with one each of L4 and L2. In Odisha, the predominant type was found to be L1 (n = 8). In A&N island L1 (n = 5) predominate followed by L2 (n = 3). In Chhattisgarh L3 lineage lead (n = 5) followed by L1 (n = 3). Whereas, the Northeast states comprising Manipur, Nagaland, and Tripura; overall exhibited L2 (n = 8) strain type followed by L3 (n = 6). Statistical analysis displayed non-significant findings between the different states and lineages (**Figure. 2**)

Gender wise distribution and Cluster examination

Almost 50 (64%) were isolated from men and 28 (26%) were women. The Male TB percentage exceeds the female case among the small sample size. Almost 16 different spoligotype patterns were identified in clinical isolates (n = 78) by the spoligotyping technique. Strains with the same spoligotype were

considered as a cluster in the study. These 78 isolates were observed to belong to 8 clusters, ranging from 2–20 isolates per cluster, while 25 were found to be unique. Out of these 8 clusters, cluster 1 and cluster 8 were found to be MDR-TB Beijing strains, and cluster 3 was found to be mono resistant CAS1India strain from Madhya Pradesh (**Table. 1**) (**Figure. 3a, 3b**). The major spoligotype families observed belonged to Beijing, CAS1_DELHI, EAI3_IND, and EAI5 family of *M. tuberculosis* strains (n = 58, 74%), followed by Central Asian strain CAS2 (n = 2, 2.9%), EAI1_SOM (n = 3, 4.3%), and other strains viz; EAI3, EAI6_BGD1, LAM3, LAM6, LAM9, T1, T2, U are present solitary strains and cumulatively contribute 13% (**Table. 2**).

Drug Susceptibility testing

The drug susceptibility tests for INH and RMP were carried out for all the 78 clinical isolates. Results exhibited 15.4% (n = 12) of clinical isolates showing resistance to INH or RMP + INH, which are first-line anti-TB drugs. The results of our DST tests identified resistance to INH (mono drug) in 3.8% isolates and multidrug resistance in 11.5% of cases. While 2.6% MDR strain was recorded among the *M. tuberculosis* isolates from women subjects, 9% *M. tuberculosis* isolates from men were found to be MDR (**Table. 3**).

Mutation of *rpoB*, *KatG* and *inhA*

According to the LPA assay, 3 types of mutations were found in the *rpoB* gene among five different tribes. MUT3 (S531L) were found in TRI062 and TRI346, whereas 2 tribal clinical isolates (TRI326, TRI345) showed MUT1 (D516V) and MUT2 were seen in TRI339. Likewise, the *katG* gene exhibited a different mutation; MUT2 (S315T2) in TRI053 whereas other clinical samples showed similar mutations.

Discussion

Epidemiological analysis of the clinical isolates aided by spoligotyping, a PCR-based genotyping method was carried out to understand the lineage-wise distribution of *M. tuberculosis* among the tribal population. According to Gagneux et al. (2007) *M. tuberculosis* can be classified into lineages 1 (L1) to lineage 7 (L7), wherein L5, L6 and L7 are the types prevalent in African countries. lineages 2 (East Asian) which includes the Beijing family of strains are associated with an increased probability of acquiring drug resistance than L3 and L4 while the least being L1 (Devi et al. 2015; Blouin et al. 2012; Firdessa et al. 2013; Comas 2004 and Munsiff 2006). In this study, *M. tuberculosis* belonging to L1 to L4 was seen in various ratios among the states. The dominance of *M. tuberculosis* lineages that are more prone to acquire drug resistance complicates the TB control program to a greater extent in that region. We observed predominance of L1 in Odhisa, Andaman/ Nicobar Island, and Madhya Pradesh; L2 was the dominant strain type in North-Eastern states, while L3 was found more in numbers at Chhattisgarh. Notably, L2 and L3 are omnipresent in all the reported states which implicates that the emergence of drug-resistant phenotypes in these tribal areas is more likely to occur requiring more stringent control measures focusing on the tribal population. Our study revealed CAS1_DELHI/ST26 *M. tuberculosis* strains belonging to L3 are circulating in Eastern and Central India (Madhya Pradesh, Manipur, and Assam district). The EAI3_IND/ ST11 mycobacterial strains of L2 prevail among the tribal patients of

Madhya Pradesh and A&N Island. Incoherence with our observation, reports of Devi et al. (2015) and Gupta et al. (2014) reported that prevalence of two clades of *M. tuberculosis* isolates belonging to L2 and L3 in Assam and Gwalior and Sheopur districts of North-Central India. Three *M. tuberculosis* strains belonging to EAI1_SOM (Eastern African Indian_Somalia) are reported in Madhya Pradesh districts. Previously, EAI1_SOM has been reported to be highly prevalent in southern regions compared to Northern India (Couvin et al. 2019). This may be due to increased commuting for varied reasons. We observed the occurrence of the CAS family of L3 among tribes of Nagaland, Rajasthan, Odisha, and Telangana (Eastern, central, western, and Southern India). EA1 strain which was previously prevalent only in the Southern Indian region (Brosch et al. 2002) was now found to be distributed in Southern, Eastern, Western, and Central India as well through our current study. Latin American-Mediterranean (LAM) strains of L4 are highly prevalent globally and regionally it constitutes an endemic pattern (Acosta et al. 2019). Similar findings in our study report LAM3, LAM6, and LAM9 in Madhya Pradesh, A&N Island, and Odisha respectively.

Complex clustering was visualized in spoligotyping data analysis. A total of eight clusters was noted by spoligotyping and these clusters were based on the state they are isolated and the type of their family. The number of strains per cluster ranged from 2–20. A total of 10 strains are designated as orphans that could not be brought under any clusters were also observed. The strain prevalent in each tribal area was the same as with the strain circulating in that respective state or the region. The number and types of the cluster in Madhya Pradesh were on the higher side and these need further investigation. The data from Madhya Pradesh showed that there exists a considerable amount of transmission among close tribal communities in India accentuating the need for constant screening of these communities to inter-communal spread among the tribes. It has two spoligotype clusters, one with CAS Delhi strain and the other with EAI strains, previous reports have shown a trend of decrease in EAI strains as we travel from south to north and increase in CAS Delhi strains as we travel from south to north of India (Singh et al. 2007). According to the above hypothesis, Madhya Pradesh should have an equal number of these strains and our data perfectly fits into the hypothesis. Since these are common strains in the community, we also predict that these strains have been transmitted from the general population to the tribal population. Similarly, we found that the cluster with Beijing strains (n = 13) is more predominant in the northeast region of India compared to other reports and also in the present study. This could be more related to the region being more geographically closer to china where Beijing strains are common as reported by Devi et al. (2015). The western part of India seems to report a high percentage of Beijing genotype (23%) besides associated with MDR-TB. The highest incidence of MDR-TB among the Beijing family of *M. tuberculosis* strains is also reported in the present study. This study report forecasts the Beijing strain prevalence over the border of eastern India and A&N Island.

Eight MDR (10.25%) *M. tuberculosis* was recognized in this work. Out of twelve drug-resistant isolates reported in this study including MDR-TB, five were from A&N Island which seems to be the foremost report from Nicobarese (ST292/EAI6_BGD1, ST64/LAM6, three from ST1/Beijing). Our report implicates that it would be a major challenge for the patients to travel to Port Blair for the initiation of MDR-TB treatment. It is extremely difficult and also a major risk for MDR-TB transmission. Moreover, three clinical

strains were ST1/Beijing from Nagaland and Tripura respectively. The other 4 mono resistant clinical isolates were, 1 ST26 /CAS1_DELHI from Madhya Pradesh and Manipur each; ST702/EAI5 from Madhya Pradesh; ST292/EAI6_BGD1 from A&N respectively. The recent report reveals 4.85% MDR and the percentage of INH resistance was found to be higher (14%) than MDR-TB in the sahariya tribal population when compared to the non-tribal (6%) population (Prakash et al. 2016). The Spoligotyping method used in this study is known to have a problem of homoplasmy and this is one of the limitations of this study. Secondary line typing methods (IS6110-RFLP or MIRU-VNTRs) are to be employed to advance this research further.

Based on the literature reviewed, this study is the most likely first of its kind to report the *M. tuberculosis* strain lineage among mixed tribes belonging to various parts of India and Andaman & Nicobar Island. On the whole, our study sheds light on the increasing drug-resistance prone L2 lineage strains, especially the Beijing strains among the tribal population across the country and the inter-communal spread of TB between the various tribes and regions of the country. The major limitation of this study is the low sample size which could be addressed in the next phase of this tribal study to arrive at any conclusion in other domicile states of India.

Declarations

Funding: Supported by ICMR Task force study under Tribal forum.

Conflicts of interest/Competing interests: None

Availability of data and material (data transparency): Available

Code availability: NA

Authors' contributions: Azger Dusthacker: Conceptualization, Methodology, Visualization, Investigation, and supervision. Ashok Kumar: Investigation. Sucharitha Kannappan Mohanvel: Data curation, writing, original draft preparation. Maghizhaveni: Supervision. S. Shivakumar Validation and data curation. Raghavi S, Azhagendran S, Vetrivel S: Project administration. Vikas Gangadhar Rao, Rajiv Yadav, Vijayachari Paluru, Anil Jacob Purthy, Tahziba Hussain, Vivek Kashyap, K. Rekha Devi, Anil Kumar Indira Krishnan, Praveen Anand, Pradeep Das, Avi Kumar Bansal: Resources. Madhuchhanda Das, Harpreet Kaur, D. Raghunath: Review and editing. Rajesh Mondal: Supervision and review & editing. Beena E Thomas: Resources and project administration.

Ethics approval: This prospective study involving human participants was revised and permitted by the Institutional Ethics Committee of the National Institute for Research in Tuberculosis, Chennai, India. The patients/participants provided their written informed approval to take part in this study. Approval Number: NIRT IEC No; 2014005.

Consent to participate (include appropriate statements): The patients/participants provided their written informed approval to take part in this study

Consent for publication (include appropriate statements): I, give my consent for the publication of identifiable details, which includes photograph(s) and/or case history and/or details within the text (“Material”) to be published in the “World Journal of Microbiology and Biotechnology”.

Acknowledgments

The authors would like to profusely thank the director of NIRT for permitting us to carry out the study and the site investigators for reaching the tribal areas. We indeed express our sincere thanks to Mr. Kannan Thiruvengadam, *Department of Statistics, NIRT for his valuable inputs on Statistical analysis.*

References

1. Ministry of tribal affairs Government of India. Annual Report 2020-21.
2. World Health Organization. Global Tuberculosis Report 2020.
3. Thomas BE, Adinarayanan S, Manogaran C, Swaminathan S. Pulmonary tuberculosis among tribals in India: A systematic review & meta-analysis. (2015) . Indian J Med Res [Internet] 141(5):614–23. Available from: <https://pubmed.ncbi.nlm.nih.gov/26139779>.
4. Rao VG, Bhat J, Yadav R, Sharma RK, Muniyandi M. (2019). Declining tuberculosis prevalence in Saharia, a particularly vulnerable tribal community in Central India: evidences for action. BMC Infect Dis [Internet] 19(1):180. Available from: <https://doi.org/10.1186/s12879-019-3815-8>.
5. Ameke S, Asare P, Aboagye SY, Otchere ID, Osei-Wusu S, Yeboah-Manu D. (2021). Molecular epidemiology of *Mycobacterium tuberculosis* complex in the Volta Region of Ghana. PLoS ONE 16 (3): e0238898. <https://doi.org/10.1371/journal.pone.0238898>.
6. Kendall EA, Fofana MO, Dowdy DW. (2015). Burden of transmitted multidrug resistance in epidemics of tuberculosis: a transmission modelling analysis. Lancet Respir Med [Internet] 3(12): 963–72. Available from: <https://pubmed.ncbi.nlm.nih.gov/26597127>
7. Sharma A, Hill A, Kurbatova E, van der Walt M, Kvasnovsky C, Tupasi TE, et al. (2017). Estimating the future burden of multidrug-resistant and extensively drug-resistant tuberculosis in India, the Philippines, Russia, and South Africa: a mathematical modelling study. Lancet Infect Dis 17(7):707–15.
8. Devi KR, Jagat P, Rinchenla B, Peggy D, Atanu S, Nitumoni G & Kanwar N. (2021). Molecular diversity of *Mycobacterium tuberculosis* complex in Sikkim, India and prediction of dominant spoligotypes using artificial intelligence. Scientific Reports 11:7365 | <https://doi.org/10.1038/s41598-021-86626-z>.
9. Gupta A, Kulkarni S, Rastogi N, Anupurba S. (2014). A study of *Mycobacterium tuberculosis* genotypic diversity & drug resistance mutations in Varanasi, North India. Indian J Med Res [Internet] 139(6):892–902.
10. Varma-Basil M, Nair D. Molecular epidemiology of tuberculosis: (2017). Opportunities & challenges in disease control. Indian J Med Res 146: 11-4. Available from: <https://www.ijmr.org.in/text.asp?2017/146/1/11/219021>.

11. Rahul G, Rabbind S A, Ravi P, Sanjay J and Pramod K.T. (2019). Spoligotyping, phenotypic and genotypic characterization of katG, rpoB gene of *M. tuberculosis*. Journal of Infection and Public Health 12: 395-402. <https://doi.org/10.1016/j.jiph.2018.12.009>.
12. Desikan P, Chauhan D, Sharma P, Panwalkar N, Gautam S, Katoch V. (2012). A pilot study to determine genetic polymorphism in *Mycobacterium tuberculosis* isolates in Central India. Indian J Med Microbiol [Internet] 1;30(4):470–3. Available from: <http://www.ijmm.org/article.asp?issn=0255-0857>
13. Said A, Hadidy G, N, Gomaa, Robert C. (2009). Strain differentiation of *Mycobacterium tuberculosis* complex isolated from sputum of pulmonary tuberculosis patients. International Journal of Infectious Diseases 13: 236-242.
14. Togun T, Beate K, Neil G S and Marc L. Anticipating the impact of the COVID-19 pandemic on TB patients and TB control programmes. 2020. Annals of Clinical Microbiology and Antimicrobials 19: 1-6.
15. Bacteriology D of. Standard Operating Protocol [Internet]. (2016). National Institute for Research in Tuberculosis Available from: <http://www.nirt.res.in/pdf/bact/SOP.pdf>
16. World Health Organization. (2007). The Use of Liquid Medium for Culture and Drug Susceptibility Testing (DST) in Low- and Medium-income Settings [Internet]. Geneva; Available from: https://www.who.int/tb/laboratory/use_of_liquid_tb_culture_summary_report.pdf?ua=1
17. Agarwal, A., Dhole TN, Sharma YK. (2014). Evaluation of p-nitro benzoic acid (pnb) inhibition test to differentiate *Mycobacterium tuberculosis* complex from non-tuberculosis mycobacteria using microscopic observation of drug susceptibility. Indian Journal of Tuberculosis 61: 232-235.
18. Kamerbeek J, Schouls L, Kolk A, van Agterveld M, van Soolingen D, Kuijper S, et al. (1997). Simultaneous detection and strain differentiation of *Mycobacterium tuberculosis* for diagnosis and epidemiology. J Clin Microbiol [Internet] 35(4):907–14. Available from: <https://pubmed.ncbi.nlm.nih.gov/9157152>.
19. Gagneux S, Small PM. (2007). Global phylogeography of *Mycobacterium tuberculosis* and implications for tuberculosis product development. Lancet Infect Dis 7(5):328–37.
20. Devi KR, Bhutia R, Bhowmick S, Mukherjee K, Mahanta J, Narain K. (2015). Genetic Diversity of *Mycobacterium tuberculosis* Isolates from Assam, India: Dominance of Beijing Family and Discovery of Two New Clades Related to CAS1_Delhi and EAI Family Based on Spoligotyping and MIRU-VNTR Typing. PLoS One [Internet] 23;10(12):e0145860. Available from: <https://doi.org/10.1371/journal.pone.0145860.20>.
21. Blouin Y; HauckY, Soler C, Fabre M, Vong R, Dehan C, Cazajous G, Massoure P- L, Kraemer P, Jenkins A, et al. (2012). Significance of the Identification in the Horn of Africa of an Exceptionally Deep Branching *Mycobacterium tuberculosis* Clade. PLOS ONE 7:e52841.
22. Firdessa R, Berg S, Hailu E, Schelling E, Gumi B, Erenso G, Gadisa E, Kiros T, Habtamu M, Hussein J, et al. (2013). *Mycobacterial* lineages causing pulmonary and extrapulmonary tuberculosis, Ethiopia. Emerg. Infect. Dis 19:460-463.

23. Comas I, Hailu E, Kiros T, Bekele S, Mekonnen W, Gumi B, Tschopp R, Ameni G, Hewinson RG, Robertson BD. (2015). Population Genomics of *Mycobacterium tuberculosis* in Ethiopia Contradicts the Virgin Soil Hypothesis for Human Tuberculosis in Sub-Saharan Africa. *Curr. Biol* 25:3260–3266.
24. Munsiff SS, Li J, Cook S V, Piatek A, Laraque F, Ebrahimzadeh A, et al. (2006). Trends in Drug-Resistant *Mycobacterium tuberculosis* in New York City, 1991–2003. *Clin Infect Dis* [Internet] 42(12):1702–10. Available from: <https://doi.org/10.1086/504325>.
25. Couvin D, Reynaud Y, Rastogi N Two tales. (2019). Worldwide distribution of Central Asian (CAS) versus ancestral East-African Indian (EAI) lineages of *Mycobacterium* phylogeographical, epidemiological and demographical characteristics. *PLoS ONE* 14 e0219706. <https://doi.org/10.1371/journal.pone.0219706>.
26. Brosch R, Gordon S V, Marmiesse M, Brodin P, Buchrieser C, Eiglmeier K, et al. (2002). A new evolutionary scenario for the *Mycobacterium tuberculosis* complex. *Proc Natl Acad Sci* [Internet] Mar 19;99(6):3684 LP – 3689. Available from: <http://www.pnas.org/content/99/6/3684.abstract>
27. Acosta CCD, Graciela R, Norma C, Viviana R, Sidra E. G. V, Marcia de B P M, Nilda J. de Romero, Nora M, Jacobus H De W, Harrison M G and Philip N S. (2019). Exploring the "Latin American Mediteerranean" family and the RDRIO lineage in *Mycobacterium tuberculosis* isolates from Paraguay, Argentina and Venezuela. *BMC Microbiology* 19: 1-13.
28. Singh UB, Arora J, Suresh N, Pant H, Rana T, Sola C, et al. (2007). Genetic biodiversity of *Mycobacterium tuberculosis* isolates from patients with pulmonary tuberculosis in India. *Infect Genet Evol* [Internet] (4):441–448. Available from: <https://doi.org/10.1016/j.meegid.2007.01.003>.
29. Prakash R, Kumar D, Gupta VK, Jain S, Chauhan DS, Tiwari PK, et al. (2016). Status of muctidrug resistant tuberculosis (MDR-TB) among the Sahariya tribe of North Central India. *J Infect Public Health* (Internet) 3: 289-97.

Tables

Table 1
State-wise cluster distribution and Spoligotyping. Number of clusters grouped based on strains

Clusters	State	Spoligotyping	ST	No in Cluster
Cluster 1**	A & N	BEIJING	1	2
Cluster 2	A & N	EAI3_IND	11	3
Cluster 3*	Madhya Pradesh	CAS1_DELHI	26	11
Cluster 4	Madhya Pradesh	EAI1_SOM	48	2
Cluster 5	Madhya Pradesh	EAI3_IND	11	7
Cluster 6	Nagaland	CAS	2758	3
Cluster 7	Odisha	EAI 5	138	2
Cluster 8**	Nagaland	BEIJING	1	2

* Monoresistant; ** MDR

S. No	Isolate Code	INH Phenotypic profile	RIF Phenotypic profile	Spoligotype	Share type/Spoligo family	Tribal Origin
1.	TRI 010	Resistant	Sensitive		ST26 /CAS1_DELHI	Madhya Pradesh
2.	TRI 042	Resistant	Sensitive		ST702/EAI5	Madhya Pradesh
3.	TRI 045	Resistant	Sensitive		ST292/EAI6_BGD1	A&N Island
4.	TRI 046	Resistant	Resistant		ST64/LAM6	A&N Island
5.	TRI 049	Resistant	Resistant		ST1/Beijing	A&N Island
6.	TRI 053	Resistant	Resistant		ST1/Beijing	A&N Island
7.	TRI 062	Resistant	Resistant		ST/Beijing	A&N Island
8.	TRI 326	Resistant	Resistant		ST1/Beijing	Nagaland
9.	TRI 336	Sensitive	Resistant		ST26/ CAS1_DELHI	Manipur
10.	TRI 345	Resistant	Resistant		ST1/Beijing	Nagaland
11.	TRI 339	Resistant	Resistant		ST1/Beijing	Tripura
12.	TRI 346	Resistant	Resistant		ST1/Beijing	Nagaland

Figures




Figure 1

a. TB tribal prevalence across India. The highlighted areas depict 10 states and A&N Island; with the distribution of strain lineage in several states, whereas the grey shaded zones were not included in the phase I study report. b. Tribal population distribution in Madhya Pradesh and Chhattisgarh. Predominant TB cultures were reported in Madhya Pradesh and Chhattisgarh. TB cultures correlated with the mixed tribal population in villages with strain lineage distribution.




Figure 2

Phylogenetic tree exhibited different states and A&N Island distributed into major lineages along with the tribal ID, octal code, and their respective strains using unweighted pair group method and arithmetic mean.




Figure 3

a. Pictorial representation of 5 complex clusters. Strains with similar spoligotyping were depicted as clusters. Each cluster depicts a different strain distribution. 5 clusters with different colours ranging from 2-20 isolates per cluster were witnessed on 78 *M. tuberculosis* isolates. b. Clusters are represented with respective octal codes and their tribal ID. Similar octal code grouped representing complex 5 clusters.